Researchers have identified a blood biomarker that predicts the risk of suicide in patients with major depressive disorder. The biomarker also can help researchers understand the molecular changes in suicide victims.
Study reports a significant decline in smoking for those with major depression and substance use disorders, signifying smoking cessation treatments and campaigns are effective in targeting those in groups considered high risk for developing nicotine addiction.
Over 22% of adults who were chronically exposed to parental domestic violence as children developed major depressive disorder later in life. 1 in 6 adults who witnessed PDV developed anxiety disorders, and over 25% later developed substance use disorders.
People with major depressive disorder who spent more time at home during a two-week period reported more severe symptoms of depression.
Alcohol use disorder is associated with a significant increase in suicidal thoughts in adults.
The antidepressant effect of psilocybin-assisted therapy, in combination with psychotherapy, appears to provide up to a year of symptom relief for some patients with major depressive disorder.
While patients with schizophrenia, major depressive disorder, and bipolar disorder experience a lack of motivation and anhedonia, the neural patterns of emotion-behavior dissociation differ between the disorders.
Researchers found alterations in different parts of the brain in males and females with severe depression. The findings also reveal a specific biomarker for depression in blood samples of women.
Hippocampal HCN channels are more highly expressed in people with major depressive disorder. Antidepressants that increase cAMP signaling interfere with TRIP8b's ability to bind to HCN channels, helping to restore cognitive ability in those with MDD.
Specific neural learning processes are linked to symptoms of depression. Improvements in the learning processes were associated with overall improvements in depression symptoms.